Top

Published in:

01-04-2014 | Research Article

The -786T > C polymorphism in the NOS3 gene is associated with increased cancer risk

Authors: Yonggang Zhang, Qingyi Jia, Pei Xue, Yuqi Liu, Tianyuan Xiong, Jiqiao Yang, Chenxi Song, Qing He, Liang Du

Published in: Tumor Biology | Issue 4/2014

Abstract

The -786T > C polymorphism in NOS3 gene may affect the DNA repair pathways and be associated with risk of cancer. However, the results of previous studies are inconsistent. The objective of this study is to investigate the association between the -786T > C polymorphism in NOS3 and risk of cancer by meta-analysis. We searched PubMed, Embase, CNKI, and Wanfang databases and the last search was updated on Sept. 20, 2013. Statistical analysis was performed using Revman4.2 and Stata10.0 software. A total of 9 case–control studies concerning 4,089 cases and 3,847 controls were included. The results suggested a significant association between the -786T > C polymorphism in NOS3 and cancer risk (CC vs. TT + CT; OR = 1.30, 95 % CI = 1.07–1.57, P = 0.007) in total analysis. In the subgroup analysis by ethnicity and cancer types, significant associations were found in the breast cancer subgroup (OR 1.51, 95 % CI 1.07–2.12; P = 0.02) and European subgroup (OR 1.26, 95 % CI 1.01–1.58; P = 0.04). The current meta-analysis suggested that the -786T > C polymorphisms in NOS3 may be a risk factor for cancer. In the future, more case–control studies are needed to validate our results.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.

Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, et al. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case–control and genetic analysis. Lancet Oncol. 2011;12(4):377–86. doi:10.1016/S1470-2045(11)70044-4.PubMedCentralPubMedCrossRef

Sun T, Hu Z, Shen H, Lin D. Genetic polymorphisms in cytotoxic T lymphocyte antigen 4 and cancer: the dialectical nature of subtle human immune dysregulation. Cancer Res. 2009;69(15):6011–4. doi:10.1158/0008-5472.CAN-09-0176.PubMedCrossRef

Kruger S, Silber AS, Engel C, Gorgens H, Mangold E, Pagenstecher C, et al. Arg462Gln sequence variation in the prostate-cancer-susceptibility gene RNASEL and age of onset of hereditary non-polyposis colorectal cancer: a case–control study. Lancet Oncol. 2005;6(8):566–72. doi:10.1016/S1470-2045(05)70253-9.PubMedCrossRef

Yang X, Li B, Si T, Liu Y, Guo Z. Association between the 8473T > C polymorphism of PTGS2 and prostate cancer risk: a meta-analysis including 24,716 subjects. Onkologie. 2013;36(4):182–6. doi:10.1159/000349951.PubMedCrossRef

Wang Z, Wang C, Zhao Z, Liu F, Guan X, Lin X, et al. Association between -251A> T polymorphism in the interleukin-8 gene and oral cancer risk: a meta-analysis. Gene. 2013;522(2):168–76. doi:10.1016/j.gene.2013.03.066.PubMedCrossRef

Ouyang FD, Yang FL, Chen HC, Khan MA, Huang FM, Wan XX, et al. Polymorphisms of DNA repair genes XPD, XRCC1, and OGG1, and lung adenocarcinoma susceptibility in Chinese population. Tumor Biol: J Int Soc Oncodev Biol Med. 2013;34(5):2843–8. doi:10.1007/s13277-013-0844-6.CrossRef

Yin QH, Liu C, Hu JB, Meng RR, Li L, Wang YJ. XPD Lys751Gln and Asp312Asn polymorphisms and gastric cancer susceptibility: a meta-analysis of case–control studies. Asian Pac J Cancer Prev : APJCP. 2013;14(1):231–6.PubMedCrossRef

Sorour A, Ayad MW, Kassem H. The genotype distribution of the XRCC1, XRCC3, and XPD DNA repair genes and their role for the development of acute myeloblastic leukemia. Genet Test Mol Biomarkers. 2013;17(3):195–201. doi:10.1089/gtmb.2012.0278.PubMedCrossRef

10.

Lee KM, Choi JY, Lee JE, Noh DY, Ahn SH, Han W, et al. Genetic polymorphisms of NOS3 are associated with the risk of invasive breast cancer with lymph node involvement. Breast cancer Res Treat. 2007;106(3):433–8. doi:10.1007/s10549-007-9506-y.PubMedCrossRef

11.

Jang MJ, Jeon YJ, Kim JW, Chong SY, Hong SP, Oh D, et al. Association of eNOS polymorphisms (−786T > C, 4a4b, 894G > T) with colorectal cancer susceptibility in the Korean population. Gene. 2013;512(2):275–81. doi:10.1016/j.gene.2012.10.032.PubMedCrossRef

12.

Lu J, Wei Q, Bondy ML, Yu TK, Li D, Brewster A, et al. Promoter polymorphism (−786T > C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer. 2006;107(9):2245–53. doi:10.1002/cncr.22269.PubMedCrossRef

13.

Ryk C, Wiklund NP, Nyberg T, de Verdier PJ. Polymorphisms in nitric-oxide synthase 3 may influence the risk of urinary bladder cancer. Nitric Oxide: Biol Chem / Off J Nitric Oxide Soc. 2011;25(3):338–43. doi:10.1016/j.niox.2011.06.003.CrossRef

14.

Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Effects of the T-786C, G894T, and Intron 4 VNTR (4a/b) polymorphisms of the endothelial nitric oxide synthase gene on the risk of prostate cancer. Urologic Oncol. 2013;31(7):1132–40. doi:10.1016/j.urolonc.2012.01.002.CrossRef

15.

Yeh CC, Santella RM, Hsieh LL, Sung FC, Tang R. An intron 4 VNTR polymorphism of the endothelial nitric oxide synthase gene is associated with early-onset colorectal cancer. Int J Cancer J Int du cancer. 2009;124(7):1565–71. doi:10.1002/ijc.24114.CrossRef

16.

Conde MC, Ramirez-Lorca R, Lopez-Jamar JM, Molero E, Ramirez-Armengol JA, Moreno Nogueira JA, et al. Genetic analysis of caveolin-1 and eNOS genes in colorectal cancer. Oncol Rep. 2006;16(2):353–9.PubMed

17.

Ghilardi G, Biondi ML, Cecchini F, DeMonti M, Guagnellini E, Scorza R. Vascular invasion in human breast cancer is correlated to T– > 786C polymorphism of NOS3 gene. Nitric oxide : biol chem / off j Nitric Oxide Soci. 2003;9(2):118–22.CrossRef

18.

Fujita S, Masago K, Hatachi Y, Fukuhara A, Hata A, Kaji R, et al. Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy. BMC Med Genet. 2010;11:167. doi:10.1186/1471-2350-11-167.PubMedCentralPubMedCrossRef

19.

Hildebrandt MA, Komaki R, Liao Z, Gu J, Chang JY, Ye Y, et al. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PloS one. 2010;5(8):e12402. doi:10.1371/journal.pone.0012402.PubMedCentralPubMedCrossRef

20.

Lee KM, Kang D, Park SK, Berndt SI, Reding D, Chatterjee N, et al. Nitric oxide synthase gene polymorphisms and prostate cancer risk. Carcinogenesis. 2009;30(4):621–5. doi:10.1093/carcin/bgp028.PubMedCentralPubMedCrossRef

21.

Brankovic A, Brajuskovic G, Nikolic Z, Vukotic V, Cerovic S, Savic-Pavicevic D et al. Endothelial nitric oxide synthase gene polymorphisms and prostate cancer risk in Serbian population. International journal of experimental pathology. 2013. doi:10.1111/iep.12045

22.

Du L, Wang H, Xiong T, Ma Y, Yang J, Huang J, et al. The polymorphisms in the MGMT gene and the risk of cancer: a meta-analysis. Tumor Biol: J Int Soc Oncodev Biol Med. 2013;34(5):3227–37. doi:10.1007/s13277-013-0893-x.CrossRef

23.

Huang J, Yang J, Wang H, Xiong T, Zhang H, Ma Y, et al. The association between the poly(A) polymorphism in the VDR gene and cancer risk: a meta-analysis. Tumor Biol: J Int Soc Oncodev Biol Med. 2013;34(3):1833–8. doi:10.1007/s13277-013-0724-0.CrossRef

Title: The -786T > C polymorphism in the NOS3 gene is associated with increased cancer risk
Authors: Yonggang Zhang
Qingyi Jia
Pei Xue
Yuqi Liu
Tianyuan Xiong
Jiqiao Yang
Chenxi Song
Qing He
Liang Du
Publication date: 01-04-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1467-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

MiR-495 regulates proliferation and migration in NSCLC by targeting MTA3

The association between cytotoxic T lymphocyte-associated antigen-4 and cervical cancer

Differential association of RANTES-403 and IL-1B-1464 polymorphisms on histological subtypes in male Korean patients with gastric cancer

Filamin A regulates MMP-9 expression and suppresses prostate cancer cell migration and invasion

Effect of cyclin G2 on proliferative ability of prostate cancer PC-3 cell

Cytochrome b5 reductase 2 is a novel candidate tumor suppressor gene frequently inactivated by promoter hypermethylation in human nasopharyngeal carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer